Performance of Comprehensive Complication Index and Clavien-Dindo Complication Scoring System in Liver Surgery for Hepatocellular Carcinoma.
Clavien-Dindo classification
comprehensive complication index
hepatocellular carcinoma
length of stay
liver surgery
morbidity
performance
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
21 Dec 2020
21 Dec 2020
Historique:
received:
19
11
2020
revised:
11
12
2020
accepted:
15
12
2020
entrez:
29
12
2020
pubmed:
30
12
2020
medline:
30
12
2020
Statut:
epublish
Résumé
We aimed to assess the ability of comprehensive complication index (CCI) and Clavien-Dindo complication (CDC) scale to predict excessive length of hospital stay (e-LOS) in patients undergoing liver resection for hepatocellular carcinoma. Patients were identified from an Italian multi-institutional database and randomly selected to be included in either a derivation or validation set. Multivariate logistic regression models and ROC curve analysis including either CCI or CDC as predictors of e-LOS were fitted to compare predictive performance. E-LOS was defined as a LOS longer than the 75th percentile among patients with at least one complication. A total of 2669 patients were analyzed (1345 for derivation and 1324 for validation). The odds ratio (OR) was 5.590 (95%CI 4.201; 7.438) for CCI and 5.507 (4.152; 7.304) for CDC. The AUC was 0.964 for CCI and 0.893 for CDC in the derivation set and 0.962 vs. 0.890 in the validation set, respectively. In patients with at least two complications, the OR was 2.793 (1.896; 4.115) for CCI and 2.439 (1.666; 3.570) for CDC with an AUC of 0.850 and 0.673, respectively in the derivation cohort. The AUC was 0.806 for CCI and 0.658 for CDC in the validation set. When reporting postoperative morbidity in liver surgery, CCI is a preferable scale.
Sections du résumé
BACKGROUND
BACKGROUND
We aimed to assess the ability of comprehensive complication index (CCI) and Clavien-Dindo complication (CDC) scale to predict excessive length of hospital stay (e-LOS) in patients undergoing liver resection for hepatocellular carcinoma.
METHODS
METHODS
Patients were identified from an Italian multi-institutional database and randomly selected to be included in either a derivation or validation set. Multivariate logistic regression models and ROC curve analysis including either CCI or CDC as predictors of e-LOS were fitted to compare predictive performance. E-LOS was defined as a LOS longer than the 75th percentile among patients with at least one complication.
RESULTS
RESULTS
A total of 2669 patients were analyzed (1345 for derivation and 1324 for validation). The odds ratio (OR) was 5.590 (95%CI 4.201; 7.438) for CCI and 5.507 (4.152; 7.304) for CDC. The AUC was 0.964 for CCI and 0.893 for CDC in the derivation set and 0.962 vs. 0.890 in the validation set, respectively. In patients with at least two complications, the OR was 2.793 (1.896; 4.115) for CCI and 2.439 (1.666; 3.570) for CDC with an AUC of 0.850 and 0.673, respectively in the derivation cohort. The AUC was 0.806 for CCI and 0.658 for CDC in the validation set.
CONCLUSIONS
CONCLUSIONS
When reporting postoperative morbidity in liver surgery, CCI is a preferable scale.
Identifiants
pubmed: 33371419
pii: cancers12123868
doi: 10.3390/cancers12123868
pmc: PMC7767420
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Br J Surg. 2013 Apr;100(5):711-8
pubmed: 23364914
Asian J Surg. 2019 Dec;42(12):1009-1016
pubmed: 31256974
Liver Int. 2019 May;39(5):894-904
pubmed: 30790410
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Surgery. 2019 Oct;166(4):663-669
pubmed: 31447105
N Engl J Med. 2011 Sep 22;365(12):1118-27
pubmed: 21992124
Ann Surg. 2021 Jan 1;273(1):112-120
pubmed: 30985367
Updates Surg. 2016 Jun;68(2):135-42
pubmed: 27294278
Eur Urol. 2020 Jan;77(1):55-65
pubmed: 31473012
Br J Surg. 2014 Jun;101(7):846
pubmed: 24817652
Ann Surg. 2018 Nov;268(5):784-791
pubmed: 30272585
Ann Surg. 2018 Nov;268(5):838-844
pubmed: 30303875
Gastroenterol Res Pract. 2018 Nov 19;2018:4396018
pubmed: 30581463
PLoS Med. 2007 Oct 16;4(10):e296
pubmed: 17941714
Eur J Surg Oncol. 2018 Oct;44(10):1580-1587
pubmed: 29861336
J Surg Res. 2020 Mar;247:397-405
pubmed: 31676144
HPB (Oxford). 2020 Sep 19;:
pubmed: 32958386
J Surg Res. 2019 Dec;244:417-424
pubmed: 31326707
Ann Surg. 2013 Jul;258(1):1-7
pubmed: 23728278
J Hepatol. 2012 Apr;56(4):908-43
pubmed: 22424438
Ann Surg. 2014 Nov;260(5):757-62; discussion 762-3
pubmed: 25379846
Ann Surg. 2020 Apr;271(4):724-731
pubmed: 30339628
World J Gastroenterol. 2019 Jun 21;25(23):2833-2838
pubmed: 31249442
J Gastrointest Surg. 2018 Sep;22(9):1593-1602
pubmed: 29766444
Eur J Surg Oncol. 2009 Nov;35(11):1179-85
pubmed: 19443173
Gastric Cancer. 2018 Jan;21(1):171-181
pubmed: 28597328
Surgery. 2011 Aug;150(2):204-16
pubmed: 21801959
Ann Surg. 2017 Nov;266(5):772-778
pubmed: 28742700
Dig Surg. 2015;32(5):361-6
pubmed: 26279268
World J Surg. 2011 Sep;35(9):2073-82
pubmed: 21656309